https://orcid.org/0000-0002-4218-4587
References
- Chan JK, Lamant L, Algar E, et al. ALK + histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood. 2008;112(7):2965–2968.
- Chang KTE, Tay AZE, Kuick CH, et al. ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion. Mod Pathol. 2019;32(5):598–608.
- Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009;15(9):3143–3149.
- Ross JS, Ali SM, Fasan O, et al. ALK fusions in a wide variety of tumor types respond to anti-ALK targeted therapy. The Oncol. 2017;22(12):1444–1450.
- Gupta GK, Xi L, Pack SD, et al. ALK-positive histiocytosis with KIF5B-ALK fusion in an adult female. Haematologica. 2019;104(11):e534–e536.
- Lucas CG, Gilani A, Solomon DA, et al. ALK-positive histiocytosis with KIF5B-ALK fusion in the central nervous system. Acta Neuropathol. 2019;138(2):335–337.
- Huang H, Gheorghe G, North PE, et al. Expanding the phenotype of ALK-positive histiocytosis: a report of 2 cases. Pediatr Dev Pathol. 2018 Sep-Oct;21(5):449–455.
- Kashima J, Yoshida M, Jimbo K, et al. ALK-positive histiocytosis of the breast: a clinicopathologic study highlighting spindle cell histology. Am J Surg Pathol. 2020. doi:10.1097/pas.0000000000001567
- Wolter NE, Ngan B, Whitlock JA, et al. Atypical juvenile histiocytosis with novel KIF5B-ALK gene fusion mimicking subglottic hemangioma. Int J Pediatr Otorhinolaryngol. 2019;126:109585.
- Jaber OI, Jarrah DA, Hiasat M, et al. ALK-positive histiocytosis: a case report and literature review. Turk Patoloji Derg. 2020. doi:10.5146/tjpath.2020.01507
- Syrykh C, Ysebaert L, Pericart S, et al. ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib. Virchows Arch. 2020. doi:10.1007/s00428-020-02937-y
- Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6(2):154–165.
- Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov. 2017;7(2):137–155.
- Garces S, Medeiros LJ, Patel KP, et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol. 2017;30(10):1367–1377.
- Durham BH, Lopez Rodrigo E, Picarsic J, et al. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med. 2019;25(12):1839–1842.